(NASDAQ: RVMD) Revolution Medicines's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 44.75%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 42.88%.
Revolution Medicines's earnings in 2025 is -$960,978,000.On average, 23 Wall Street analysts forecast RVMD's earnings for 2025 to be -$1,103,952,746, with the lowest RVMD earnings forecast at -$1,091,251,635, and the highest RVMD earnings forecast at -$1,002,749,829. On average, 23 Wall Street analysts forecast RVMD's earnings for 2026 to be -$1,263,963,549, with the lowest RVMD earnings forecast at -$1,445,529,510, and the highest RVMD earnings forecast at -$911,406,221.
In 2027, RVMD is forecast to generate -$1,162,277,332 in earnings, with the lowest earnings forecast at -$1,619,826,646 and the highest earnings forecast at -$261,851,676.